Evidence map›Paper›PMID 25889862›Full record

ArticleRespiratory research2015

Anti-inflammatory effects of novel curcumin analogs in experimental acute lung injury.

Yali Zhang, Dandan Liang, Lili Dong, Xiangting Ge, Fengli Xu, Wenbo Chen, Yuanrong Dai, Huameng Li, Peng Zou, Shulin Yang and 1 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Respiratory research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 90 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Journal of virology · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Therapeutic potential of curcumin in ARDS and COVID-19.Clinical and experimental pharmacology & physiology · 2023
    Review
  11. The Effects of Curcumin on Inflammasome: Latest Update.Molecules (Basel, Switzerland) · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. The Effect ofEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yali ZhangChemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. ya-li000@163.com.
Dandan LiangChemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. liangdandan90@163.com.
Lili DongThe 2nd Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. luckydlily@163.com.
Xiangting GeThe 2nd Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. 228302061@qq.com.
Fengli XuThe 2nd Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. 18368719239@163.com.
Wenbo ChenChemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. 932927513@qq.com.
Yuanrong DaiThe 2nd Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. yuanrongdai2000@163.com.
Huameng LiChemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. huameng@yahoo.com.
Peng ZouSchool of Environmental and Biological Engineering, Nanjing University of Science and Technology, Nanjing, Jiangsu, 210094, China. top_zoupeng@163.com.
Shulin YangSchool of Environmental and Biological Engineering, Nanjing University of Science and Technology, Nanjing, Jiangsu, 210094, China. shulin_yang@126.com.
Guang LiangChemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. wzmcliangguang@163.com.
Wenzhou Medical University · CNNanjing University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute lung injury (ALI) and its most severe form acute respiratory distress syndrome (ARDS) have been the leading cause of morbidity and mortality in intensive care units (ICU). Currently, there is no effective pharmacological treatment for acute lung injury. Curcumin, extracted from turmeric, exhibits broad anti-inflammatory properties through down-regulating inflammatory cytokines. However, the instability of curcumin limits its clinical application.

methodsA series of new curcumin analogs were synthesized and screened for their inhibitory effects on the production of TNF-α and IL-6 in mouse peritoneal macrophages by ELISA. The evaluation of stability and mechanism of active compounds was determined using UV-assay and Western Blot, respectively. In vivo, SD rats were pretreatment with c26 for seven days and then intratracheally injected with LPS to induce ALI. Pulmonary edema, protein concentration in BALF, injury of lung tissue, inflammatory cytokines in serum and BALF, inflammatory cell infiltration, inflammatory cytokines mRNA expression, and MAPKs phosphorylation were analyzed. We also measured the inflammatory gene expression in human pulmonary epithelial cells.

resultsIn the study, we synthesized 30 curcumin analogs. The bioscreeening assay showed that most compounds inhibited LPS-induced production of TNF-α and IL-6. The active compounds, a17, a18, c9 and c26, exhibited their anti-inflammatory activity in a dose-dependent manner and exhibited greater stability than curcumin in vitro. Furthermore, the active compound c26 dose-dependently inhibited ERK phosphorylation. In vivo, LPS significantly increased protein concentration and number of inflammatory cells in BALF, pulmonary edema, pathological changes of lung tissue, inflammatory cytokines in serum and BALF, macrophage infiltration, inflammatory gene expression, and MAPKs phosphorylation . However, pretreatment with c26 attenuated the LPS induced increase through ERK pathway in vivo. Meanwhile, compound c26 reduced the LPS-induced inflammatory gene expression in human pulmonary epithelial cells.

conclusionsThese results suggest that the novel curcumin analog c26 has remarkable protective effects on LPS-induced ALI in rat. These effects may be related to its ability to suppress production of inflammatory cytokines through ERK pathway. Compound c26, with improved chemical stability and bioactivity, may have the potential to be further developed into an anti-inflammatory candidate for the prevention and treatment of ALI.

Indexed as

Acute Lung InjuryAnimalsAnti-Inflammatory AgentsBronchoalveolar Lavage FluidCells, CulturedCurcuminDisease Models, AnimalEnzyme ActivationEpithelial CellsGene Expression RegulationHumansInflammation MediatorsInterleukin-1betaInterleukin-6LipopolysaccharidesLungAnti-Inflammatory AgentsCurcuminIL1B protein, humanIL6 protein, humanInflammation MediatorsInterleukin-1betaInterleukin-6interleukin-6, mouseLipopolysaccharidesMitogen-Activated Protein KinasesRNA, MessengerTumor Necrosis Factor-alpha

Identifiers

PMID25889862
PMCPMC4391684
OpenAlexW1986049909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.